Financial Performance - For the year ended December 31, 2023, the company's revenue was RMB 166,917,000, a decrease of 21.5% compared to RMB 212,519,000 in 2022[4] - The gross profit for the same period was RMB 27,035,000, representing a significant increase of 53.5% from RMB 17,571,000 in the previous year[4] - The net loss for the year was RMB 18,626,000, an improvement of 46.6% compared to a net loss of RMB 34,851,000 in 2022[4] - Total revenue for the year 2023 was RMB 166,917,000, a decrease of 21.5% from RMB 212,519,000 in 2022[22] - Revenue from inflatable products and related accessories was RMB 150,860,000, down from RMB 212,051,000 in the previous year, representing a decline of 29%[22] - The group reported a total loss before tax of RMB 18,408,000 for the year 2023, compared to a loss of RMB 35,768,000 in 2022, indicating an improvement[26] - The group reported a net loss attributable to owners of the company of RMB 18,626,000 in 2023, an improvement from a loss of RMB 34,851,000 in 2022[42] - The company reported a significant impairment loss on non-financial assets of RMB 10,223,000 in 2023, compared to RMB 12,215,000 in 2022, a decrease of 16.3%[33] - Other income and gains for 2023 totaled approximately RMB 5,468,000, a decrease of about RMB 3,345,000 or 38.0% from RMB 8,813,000 in 2022[55] Assets and Liabilities - The company's total assets as of December 31, 2023, were RMB 183,775,000, a decrease from RMB 190,846,000 in 2022[6] - Current assets increased to RMB 164,537,000 from RMB 152,522,000 in the previous year, indicating a growth of 7.0%[6] - The total equity attributable to owners decreased to RMB 104,665,000 from RMB 123,148,000, a decline of 15.0%[7] - The group’s total liabilities amounted to RMB 79,110,000, with RMB 60,486,000 attributed to reportable segments[29] - Trade receivables decreased to RMB 17,707,000 in 2023 from RMB 22,738,000 in 2022, indicating a reduction of 22.1%[44] Cash Flow and Financing - The company’s cash and bank balances rose to RMB 56,323,000, up from RMB 29,385,000 in 2022, reflecting a significant increase of 91.7%[6] - Interest income from bank deposits for the year was RMB 753,000, an increase from RMB 56,000 in the previous year[26] - Interest income from bank deposits rose to RMB 753,000 in 2023 compared to RMB 56,000 in 2022, marking a significant increase of 1,241.1%[38] - The company’s financing costs, specifically lease liabilities interest, decreased to RMB 1,015,000 in 2023 from RMB 1,607,000 in 2022, a reduction of 37%[39] - The current ratio as of December 31, 2023, was approximately 2.44, down from 2.83 in 2022, indicating a decrease in liquidity[63] Business Operations - The company has been focusing on the manufacturing and sales of inflatable products and dental clinic services, indicating a strategic emphasis on these sectors[11] - The dental clinic services segment generated revenue of RMB 9,695,000, while sales of medical equipment and dental materials contributed RMB 1,450,000 and RMB 4,595,000 respectively[22] - The company completed the acquisition of Hong Kong Shengke Holdings Limited in January 2023, entering the dental clinic services sector, which is expected to provide new revenue streams[50] Employee and Governance - As of December 31, 2023, the company had 544 full-time employees, a decrease from 571 in 2022, with total employee compensation amounting to approximately RMB 42,001,000, down from RMB 50,993,000 in 2022[74] - The company has confirmed compliance with the GEM Listing Rules regarding the trading of securities by directors, with no reported violations in 2023[82] - The company has adhered to the corporate governance code as per the GEM Listing Rules, confirming compliance in 2023[86] - The audit committee was established on June 20, 2017, and consists of three independent non-executive directors as of 2023[87] - The audit committee's main responsibility is to review and supervise the group's financial reporting and internal control procedures[87] Future Outlook - The company plans to apply all other revised Hong Kong Financial Reporting Standards in the foreseeable future without significant impact on the consolidated financial statements[17] - The company has proposed to issue bonds with a total principal amount of up to HKD 40,000,000 at a 5% coupon rate over 36 months, with an introduction fee of HKD 2,000,000 payable to the agent[70] Miscellaneous - The company has not established any formal foreign exchange hedging policy, which limits its ability to mitigate foreign exchange risks due to the non-convertibility of the Renminbi[72] - No credit loss provisions were recognized for trade and other receivables in 2023, compared to RMB 547,000 in provisions in 2022, indicating a stable collection history from customers[73] - The company has not granted any stock options under its stock option plan since its adoption on November 15, 2017[80] - The annual general meeting is scheduled for June 21, 2024, with a suspension of share transfer registration from June 18 to June 21, 2024[85] - The consolidated financial statements for the year ended December 31, 2023, have been reviewed by the auditors, confirming consistency with the audited financial statements[89] - The board expresses gratitude to the management and staff for their dedication and to shareholders, suppliers, customers, and banks for their ongoing support[91] - The announcement will be published on the Hong Kong Stock Exchange website for at least seven days from the date of publication[92]

Financial Performance - Revenue for the three months ended September 30, 2023, was RMB 26,481,000, a decrease of 31.3% compared to RMB 38,594,000 for the same period in 2022[4] - Gross profit for the nine months ended September 30, 2023, was RMB 17,843,000, down 14.7% from RMB 20,894,000 in the same period of 2022[4] - The net loss for the nine months ended September 30, 2023, was RMB 8,526,000, compared to a net loss of RMB 8,347,000 for the same period in 2022, indicating a slight increase in losses[4] - The company reported a basic and diluted loss per share of RMB 0.89 for the nine months ended September 30, 2023, compared to RMB 1.04 for the same period in 2022[4] - The company’s total revenue for the nine months ended September 30, 2023, was RMB 121,363,000, down 33.6% from RMB 182,495,000 in the same period of 2022[4] - The adjusted pre-tax loss for the group was RMB 8,236,000 for the first nine months of 2023, compared to a loss of RMB 7,765,000 in the same period of 2022[15] - The company reported a net loss attributable to shareholders of RMB 8,526,000 for the first nine months of 2023, compared to a loss of RMB 8,347,000 in the same period of 2022[26] - The group recorded a loss of approximately RMB 8,526,000 for the period, a decrease of 2.14% compared to a loss of RMB 8,347,000 in the same period of 2022[38] Revenue Breakdown - Revenue from inflatable products decreased to RMB 113,022,000 in Q3 2023 from RMB 182,575,000 in Q3 2022, representing a decline of 38.3%[15] - Revenue from dental clinic services was RMB 8,362,000 in the first nine months of 2023, with no revenue reported in the same period of 2022[15] - Revenue from external customers in China increased to RMB 15,483,000 in the first nine months of 2023, compared to RMB 8,917,000 in the same period of 2022, an increase of 73.5%[19] - Revenue from the sale of inflatable products and related accessories was approximately RMB 113,001,000, down RMB 69,494,000 or 38.1% from RMB 182,495,000 in the same period last year[30] - The group's revenue for the period was approximately RMB 121,363,000, a decrease of about RMB 61,132,000 or 33.5% compared to RMB 182,945,000 in the corresponding period of 2022[30] Expenses - Distribution and selling expenses for the nine months ended September 30, 2023, were RMB 15,183,000, a decrease of 22.9% from RMB 19,687,000 in the same period of 2022[4] - Administrative expenses for the nine months ended September 30, 2023, were RMB 13,955,000, down 8.1% from RMB 15,195,000 in the same period of 2022[4] - Distribution and selling expenses amounted to approximately RMB 15,183,000, a decrease of about RMB 4,504,000 or 22.9% from RMB 19,687,000 in the same period of 2022[35] - Administrative expenses were approximately RMB 13,955,000, a decrease of about RMB 1,240,000 or 8.2% compared to RMB 15,195,000 in the same period last year[36] Equity and Dividends - Total equity as of September 30, 2023, was RMB 116,216,000, a decrease from RMB 118,709,000 as of January 1, 2022[5] - The company did not recommend any dividend payments during the period, consistent with the previous year[27] - The board decided not to declare any dividends for the period[40] Strategic Initiatives - The company continues to focus on the dental industry and aims to enhance its market position through strategic initiatives and product development[9] - The company aims to enhance competitiveness through product differentiation and innovation in the health sector[29] - In January 2023, the company completed the acquisition of all shares of Hong Kong Shengke Holdings Limited and its wholly-owned subsidiary Guangzhou Lide Dental Clinic[41] - The company completed the acquisition of Hong Kong Shengke Holdings Limited in January 2023, expanding into the dental care industry and creating new revenue streams[29] Governance and Compliance - The Audit Committee was established on June 20, 2017, chaired by independent non-executive director Ms. Lian Jingyu, ensuring compliance with GEM listing rules and corporate governance codes[54] - The unaudited condensed consolidated financial statements have been reviewed by the Audit Committee, confirming adherence to applicable accounting standards and sufficient disclosure[54] - The board of directors includes executive directors Ms. Yan Ping, Mr. Liu Yaoguang, and Mr. Xiao Jiansheng, along with independent non-executive directors[55]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內 容而引致的任何損失承擔任何責任。 China Oral Industry Group Holdings Limited 中 國 口 腔 產 業 集 團 控 股 有 限 公 司 （於開曼群島註冊成立的有限公司） （股份代號：8406） 截至二零二三年九月三十日止九個月之 第三季度業績公告 香港聯合交易所有限公司（「聯交所」）GEM的特色 GEM的定位，乃為中小型公司提供一個上市的市場，此等公司相比起其他在聯交所上市的公司可能 帶有較高投資風險。有意投資的人士應了解投資於該等公司的潛在風險，並應經過審慎周詳考慮後 方作出投資決定。 由於GEM上市公司一般為中小型公司，於GEM買賣的證券可能會較於主板買賣的證券承受較大的市 場波動風險，同時無法保證於GEM買賣的證券會有高流通量的市場。 本公告之資料乃遵照聯交所GEM證券上市規則（「GEM上市規則」）而刊載，旨在提供有關中國口腔產 業集團控股有限公司（「本公司」及連同其附屬公司，統稱為「本集團 ...

Financial Performance - For the six months ended June 30, 2023, the company reported revenue of RMB 94,882,000, a decrease of 34% compared to RMB 143,901,000 for the same period in 2022[9]. - The gross profit for the same period was RMB 13,340,000, down 26% from RMB 17,989,000 in 2022, resulting in a gross margin of approximately 14.1%[9]. - The company incurred a loss before tax of RMB 3,359,000 for the six months ended June 30, 2023, compared to a loss of RMB 2,350,000 in the prior year, indicating a worsening financial performance[9]. - The total comprehensive loss for the period was RMB 2,287,000, compared to a loss of RMB 400,000 in the same period of 2022[9]. - The company reported a basic and diluted loss per share of RMB 0.37 for the six months ended June 30, 2023, compared to RMB 0.36 in the same period of 2022[9]. - The company reported a loss of RMB 3,584,000 for the six months ended June 30, 2023, compared to a loss of RMB 2,884,000 for the same period in 2022, reflecting an increase in losses of approximately 24.2%[14]. - The company’s total comprehensive income for the six months ended June 30, 2023, was a loss of RMB 2,287,000, compared to a loss of RMB 400,000 for the same period in 2022, indicating a worsening of approximately 471.8%[14]. Assets and Liabilities - As of June 30, 2023, the company's total assets amounted to RMB 184,914,000, a decrease from RMB 190,846,000 at the end of 2022[11]. - As of June 30, 2023, the company's non-current liabilities decreased to RMB 11,898,000 from RMB 13,846,000 as of December 31, 2022, representing a reduction of approximately 14.0%[12]. - The net asset value as of June 30, 2023, was RMB 120,861,000, down from RMB 123,148,000 at the end of 2022, indicating a decline of about 1.9%[12]. - The total liabilities as of June 30, 2023, were RMB 64,053,000, down from RMB 67,698,000 as of December 31, 2022[30]. - The total trade receivables as of June 30, 2023, were RMB 23,165,000, slightly down from RMB 23,579,000 as of December 31, 2022, a decrease of 1.8%[49]. - The total trade payables as of June 30, 2023, were RMB 17,990,000, down 20.0% from RMB 22,503,000 as of December 31, 2022[52]. Cash Flow and Liquidity - The company's cash and bank balances increased significantly to RMB 69,923,000 from RMB 29,385,000 at the end of 2022, indicating improved liquidity[11]. - Operating cash flow for the six months ended June 30, 2023, was RMB 22,683,000, significantly higher than RMB 9,749,000 for the same period in 2022, marking an increase of about 132.5%[17]. - The company’s cash and cash equivalents increased to RMB 69,923,000 as of June 30, 2023, from RMB 34,479,000 at the end of 2022, representing a growth of approximately 102.5%[17]. - The company’s financing cash outflow for the six months ended June 30, 2023, was RMB 2,645,000, slightly lower than RMB 2,782,000 for the same period in 2022[17]. Revenue Segments - Revenue from the sale of inflatable products and related accessories was approximately RMB 89,791,000, down RMB 54,110,000 or 34.6% from the previous year's RMB 143,901,000[57]. - Revenue from dental clinic services was approximately RMB 5,091,000, accounting for about 5.4% of total revenue[57]. - The segment revenue from the sale of inflatable products was RMB 89,804,000 for the six months ended June 30, 2023, down from RMB 143,970,000 in the same period of 2022, representing a decline of 37.6%[30]. - The segment performance for the inflatable products showed a loss of RMB 2,929,000 for the six months ended June 30, 2023, compared to a profit of RMB 1,194,000 in the same period of 2022[30]. Expenses - Distribution and selling expenses totaled approximately RMB 10,316,000, a decrease of RMB 2,860,000 or 21.7% from RMB 13,176,000 in the previous year[62]. - Administrative expenses for the period were approximately RMB 9,188,000, down RMB 891,000 or 8.8% from RMB 10,079,000 in the corresponding period of 2022[63]. - The cost of goods sold for the six months ended June 30, 2023, was RMB 81,542,000, down 35.2% from RMB 125,912,000 in the same period of 2022[42]. Corporate Governance and Compliance - The audit committee, consisting of three independent non-executive directors, reviewed the unaudited financial results for the six months ended June 30, 2023, ensuring compliance with applicable accounting standards[89]. - The company has adhered to the corporate governance code as per GEM Listing Rules during the reporting period[87]. - The company has complied with the trading standards for directors as per GEM Listing Rules during the reporting period[85]. Employee Information - As of June 30, 2023, the group had 567 full-time employees, a decrease from 571 employees as of December 31, 2022[77]. - Total employee compensation for the six months ended June 30, 2023, was approximately RMB 22,530,000, down from approximately RMB 31,724,000 in the same period of 2022[77]. Shareholder Information - Ms. Yan Ping holds a 44.23% equity interest in the company, representing 424,560,000 shares out of 960,000,000 issued shares as of June 30, 2023[79]. - There were no other individuals or entities holding more than 5% of the issued share capital of the company as of June 30, 2023[81]. Other Information - The company did not recommend any interim dividend for the six months ended June 30, 2023, consistent with the previous year[45]. - The company has not granted any stock options under the stock option plan since its adoption on November 15, 2017[83]. - The company has established a stock option plan to provide additional incentives to qualified participants for their contributions[82].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內 容而引致的任何損失承擔任何責任。 China Oral Industry Group Holdings Limited 中 國 口 腔 產 業 集 團 控 股 有 限 公 司 （於開曼群島註冊成立的有限公司） （股份代號：8406) 截至二零二三年六月三十日止六個月 中期業績公告 香港聯合交易所有限公司（「聯交所」）GEM的特色 GEM的定位，乃為相比起其他於聯交所上市的公司帶有較高投資風險的中小型公司提供一個上市的 市場。有意投資的人士應了解投資於該等公司的潛在風險，並應經過審慎周詳考慮後方作出投資決 定。 由於GEM上市公司一般為中小型公司，於GEM買賣的證券可能會較於主板買賣的證券承受較大的市 場波動風險，同時無法保證於GEM買賣的證券會有高流通量的市場。 本公告之資料乃遵照聯交所GEM證券上市規則（「GEM上市規則」）而刊載，旨在提供有關中國口腔 產業集團控股有限公司（前稱為合寶豐年控股有限公司）（「本公司」，連同其附屬公司，「 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因依賴該等內 容而引致的任何損失承擔任何責任。 China Oral Industry Group Holdings Limited 中 國 口 腔 產 業 集 團 控 股 有 限 公 司 （於開曼群島註冊成立的有限公司） （股份代號：8406) 須予披露交易 及 有關截至二零二二年十二月三十一日止年度之年度業績公告之補充公告 須予披露交易 深圳拓盛採購協議 於二零二二年十月十七日，本公司間接全資附屬公司深圳金軒鼎（作為買方）與獨立第三方深圳拓 盛（作為賣方）訂立深圳拓盛採購協議，以總代價人民幣13.42百萬元（含增值稅）購買若干口腔護理 相關設備。 工商銀行金融產品 於二零二二年度，本公司間接全資附屬公司中山新宏達認購工商銀行金融產品，為工商銀行發行 的無固定期限理財產品。工商銀行金融產品於二零二二年十二月三十一日的公平值總額約為人民 幣30.1百萬元。 ...

Financial Performance - The company reported revenue of RMB 62,046 thousand for the three months ended March 31, 2023, a decrease of 20.3% compared to RMB 77,746 thousand in the same period of 2022[4]. - Gross profit for the same period was RMB 8,718 thousand, down 9.7% from RMB 9,651 thousand year-over-year[4]. - The company incurred a loss before tax of RMB 815 thousand, an improvement from a loss of RMB 1,131 thousand in the previous year[4]. - The net loss for the period was RMB 1,024 thousand, compared to a net loss of RMB 1,490 thousand in the same period last year, indicating a 31.2% reduction in losses[4]. - The company reported a total comprehensive loss of RMB 1,316 thousand for the period, compared to RMB 1,835 thousand in the same period last year, reflecting a 28.4% improvement[4]. - The basic and diluted loss per share was RMB 0.11, an improvement from RMB 0.19 in the previous year[4]. - The company's revenue for the first quarter of 2023 was approximately RMB 62,046,000, a decrease of about RMB 15,700,000 or 20.2% compared to RMB 77,746,000 in the same period of 2022[25]. - Revenue from inflatable amusement products was approximately RMB 58,304,000, down RMB 16,766,000 or 22.3% year-on-year, accounting for about 94.0% of total revenue[25]. - The gross profit for the period was approximately RMB 8,718,000, a decrease of about RMB 933,000 from RMB 9,651,000 in the same period of 2022, with a gross margin of 14.1%[29]. - The company recorded a loss of approximately RMB 1,024,000 for the period, a reduction of 31.3% compared to a loss of RMB 1,490,000 in the same period of 2022[34]. - The cost of sales was approximately RMB 53,328,000, a decrease of about RMB 14,767,000 or 21.7% compared to RMB 68,095,000 in the same period of 2022[27]. - Other income and gains totaled approximately RMB 321,000, a decrease of about RMB 68,000 or 17.5% compared to RMB 389,000 in the same period of 2022[30]. - Distribution and selling expenses amounted to approximately RMB 4,840,000, a decrease of about RMB 541,000 or 10.1% compared to RMB 5,381,000 in the same period of 2022[31]. - Administrative expenses were approximately RMB 4,685,000, a decrease of about RMB 670,000 or 12.5% compared to RMB 5,355,000 in the same period of 2022[32]. Revenue Sources - Revenue from the sale of inflatable products and related accessories was RMB 60,325 thousand, down 22.5% from RMB 77,786 thousand in the previous year[13]. - Revenue from dental clinic services amounted to RMB 1,720 thousand, which was not reported in the previous year[13]. - Revenue from North America increased significantly to RMB 50,541 thousand, up 34.8% from RMB 37,511 thousand in the same period of 2022[15]. Corporate Governance - The company did not recommend the payment of any interim dividend for the period[22]. - As of March 31, 2023, Risen Thrive Limited holds 424,560,000 shares, representing 44.23% of the company's total issued shares of 960,000,000[39]. - Ms. Yan Ping is the beneficial owner of all issued shares of Risen Thrive Limited and is considered to hold rights to all shares held by the company[40]. - No other individuals or entities hold 5% or more of the company's issued share capital as of March 31, 2023[42]. - The company has not granted any stock options under the stock option plan since its adoption on November 15, 2017[44]. - The company has complied with the corporate governance code as per GEM Listing Rules during the reporting period[49]. - The Audit Committee, established on June 20, 2017, has reviewed the unaudited financial results and confirmed compliance with applicable accounting standards[50]. - There were no purchases, sales, or redemptions of the company's listed securities during the reporting period[47]. - The company has not disclosed any changes in the information of directors or key executives that require disclosure under GEM Listing Rules[43]. - The company has confirmed that all directors complied with the trading standards during the reporting period[46]. - The Audit Committee includes independent non-executive directors with appropriate professional qualifications or financial management expertise[50]. Acquisitions - The company completed the acquisition of HongKong Eko Holding Co., Limited in January 2023, which is expected to provide new revenue sources in the dental care industry[24].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因依賴該等內 容而引致的任何損失承擔任何責任。 China Oral Industry Group Holdings Limited 中 國 口 腔 產 業 集 團 控 股 有 限 公 司 （於開曼群島註冊成立的有限公司） （股份代號：8406) 截至二零二三年三月三十一日止三個月 第一季度業績公告 香港聯合交易所有限公司（「聯交所」）GEM的特色 GEM的定位，乃為中小型公司提供一個上市的市場，此等公司相比起其他在聯交所上市的公司可能 帶有較高投資風險。有意投資的人士應了解投資於該等公司的潛在風險，並應經過審慎周詳考慮後 方作出投資決定。 由於GEM上市公司一般為中小型公司，於GEM買賣的證券可能會較於主板買賣的證券承受較大的市 場波動風險，同時無法保證於GEM買賣的證券會有高流通量的市場。 本公告之資料乃遵照聯交所GEM證券上市規則（「GEM上市規則」）而刊載，旨在提供有關中國口腔產 業集團控股有限公司（「本公司」及連同其附屬公司，統稱為「本集團 ...

Financial Performance - The total revenue for the year ended December 31, 2022, was approximately RMB 212,519,000, a decrease of about RMB 82,398,000 compared to RMB 294,917,000 in 2021, representing a decline of approximately 27.9%[12] - The loss for the year was approximately RMB 34,851,000, an increase of about RMB 32,718,000 or 1,533.9% compared to a loss of RMB 2,133,000 in 2021[12] - Gross profit for the year was approximately RMB 17,571,000, a decrease of about RMB 42,286,000 from RMB 59,857,000 in the previous year, resulting in a gross margin of 8.3%, down approximately 12% from 20.3%[25] - Other income and gains totaled approximately RMB 8,813,000, an increase of about RMB 6,603,000 or 298.8% compared to RMB 2,210,000 in the previous year[26] - Distribution and selling expenses amounted to approximately RMB 23,461,000, a decrease of about RMB 8,192,000 or 25.9% from RMB 31,653,000 in the previous year[27] - The company recorded impairment losses of approximately RMB 12,372,000 on property, plant, and equipment, an increase of about RMB 8,572,000 from RMB 3,800,000 in the previous year[33] - The group’s current ratio as of December 31, 2022, was approximately 2.83, compared to 2.58 as of December 31, 2021[36] - Capital expenditure for the year was approximately RMB 616,000, down from RMB 1,792,000 in the previous year[38] - The company recorded revenue from overseas customers of approximately RMB 202,544,000, accounting for 95.3% of total revenue, compared to 89.8% in the previous year[83] - Total revenue from the company's top five customers contributed approximately 60.8% of total revenue, up from 47.8% in the previous year[83] - The company has experienced a decline in revenue from overseas sales compared to the previous year, which was RMB 264,925,000[83] Business Strategy and Operations - The company plans to continue its inflatable products business in 2023 while further expanding into the health care industry, particularly in domestic oral care in China[13] - The company emphasizes maintaining high-quality standards for all products and aims to provide quality products for the oral care industry in the future[19] - The production base is located in Dongcheng Industrial Park, Zhongshan City, Guangdong Province, where the company manufactures its inflatable products[18] - The company has nearly 20 years of experience in designing, manufacturing, and selling high-quality inflatable amusement products and other inflatable products[18] - The company is committed to strict quality control procedures during the production process to enhance competitiveness through product differentiation and innovation[18] - The ongoing global pandemic has had varying degrees of impact on the company's main business operations[18] - The company plans to expand into medical and health-related services, including investments in dental clinics and health management service platforms[72] Shareholder and Investment Information - The company acknowledges the continued support from shareholders, customers, business partners, and suppliers[15] - The board of directors has confirmed the accuracy and completeness of the report's information after reasonable inquiries[3] - The group entered into an investment agreement to acquire the entire equity of a related company in the dental services sector, paying a deposit of RMB 13,000,000[43] - As of December 31, 2022, the company held significant investments in non-listed financial products amounting to RMB 30,899,000, with a fair value gain recognized in profit or loss of RMB 231,000 during the year[45] - The company did not hold any significant investments in 2021[46] - There are no major investment or capital asset plans for the upcoming year[47] Foreign Exchange and Credit Risk - Approximately 95% of the company's revenue for the year ended December 31, 2022, was denominated in USD, while production costs were in RMB, exposing the company to significant foreign exchange risk[48] - The company has not established any formal foreign exchange hedging policy or conducted hedging activities during the year due to cost-effectiveness considerations[48] - The company continues to face limited ability to mitigate foreign exchange risks due to the non-convertibility of the RMB[48] - The company maintains a policy of only engaging with customers that have suitable credit records to minimize credit risk[51] - The company recognized a credit loss provision for trade receivables of approximately RMB 547,000 for the year, compared to RMB 242,000 in the previous year[51] Employee and Compensation Information - The total employee compensation for the year ended December 31, 2022, was approximately RMB 50,993,000, down from RMB 75,797,000 in 2021, with a reduction in full-time employees from 953 to 571[52] - The company has implemented training programs to enhance employee skills and knowledge, with an annual training plan tailored to departmental needs[53] - The compensation policy includes fixed components (base salary) and variable components (discretionary bonuses and other rewards), considering factors such as experience, responsibilities, individual performance, and overall market conditions[126] - The senior management's salary ranges include two individuals earning up to HKD 1,000,000, one earning between HKD 1,000,001 and HKD 1,500,000, and three others in unspecified ranges[124] Corporate Governance - The board consists of three independent non-executive directors, ensuring over one-third of the board is independent, with at least one possessing relevant financial expertise[150] - The board is responsible for monitoring financial performance and internal controls, emphasizing the importance of independent judgment in strategy and risk management[150] - The company is committed to maintaining high corporate governance standards, regularly reviewing policies and compliance with legal regulations[152] - The company has established a director independence assessment mechanism to enhance board effectiveness and protect shareholder interests[161] - The company has provided sufficient resources for all committees to fulfill their duties effectively[167] - The audit committee held 5 meetings during the year to review the company's annual performance, interim results, and internal control procedures[167] - The audit committee concluded that the consolidated financial statements for the year ended December 31, 2022, comply with applicable accounting standards and GEM listing rules[168] - The company has engaged an independent consultant to review its internal control system, including financial and operational monitoring[188] Board Composition and Diversity - The board consists of 6 members from China, with 2 male and 4 female directors[200] - There are 3 executive directors and 3 non-executive directors on the board[200] - The age distribution includes 4 directors aged 41-50 and 2 directors aged 51-60[200] - The board has diverse industry experience, with 4 members in business management, 1 in accounting and finance, and 1 in healthcare[200] - The nomination committee has reviewed the board composition and found it to be diverse in terms of gender, industry experience, and skills[200] Miscellaneous - The company made a charitable donation of RMB 50,000 during the year ended December 31, 2022, consistent with the previous year's donation[140] - The company confirmed compliance with the public float requirements as per GEM listing rules as of the report date[142] - All independent non-executive directors have confirmed their independence according to GEM listing rules[143] - The company's consolidated financial statements for the year ended December 31, 2022, were audited by Guo Wei CPA, who will be proposed for reappointment at the 2023 annual general meeting[144]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因依賴該等內 容而引致的任何損失承擔任何責任。 China Oral Industry Group Holdings Limited 中 國 口 腔 產 業 集 團 控 股 有 限 公 司 （於開曼群島註冊成立的有限公司） （股份代號：8406） 截至二零二二年十二月三十一日止年度之年度業績公告 中國口腔產業集團控股有限公司（「本公司」，連同其附屬公司，統稱「本集團」）董事（「董事」）會（「董事 會」）謹此宣佈本公司及其附屬公司截至二零二二年十二月三十一日止年度的經審核年度業績。 本公告列載本公司二零二二年年度報告（「年報」）全文，符合聯交所GEM證券上市規則（「GEM上市 規則」）中有關年度業績初步公告附載資料的相關要求。載有GEM上市規則規定資料的年報的印刷版 本，將於適當時候以GEM上市規則所規定方式寄發予本公司股東。 承董事會命 中國口腔產業集團控股有限公司 主席兼執行董事 嚴萍 香港，二零二三年三月二十九日 於本公告日期，董事會包括執行董事 ...